lisdexamfetamine
Megjelenés
| Clinical data | |
|---|---|
| Trade names | Vyvanse, Elvanse, Tyvense, others |
| Other names | L-Lysine-d-amphetamine; (2S)-2,6-Diamino-N-[(2S)-1-phenylpropan-2-yl]hexanamide N-[(2S)-1-Phenyl-2-propanyl]-L-lysinamide |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a607047 |
| License data | |
| Pregnancy category |
|
| Dependence liability | Moderate |
| Addiction liability | Moderate |
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | Oral: 96.4% |
| Protein binding | 20% (as dextroamphetamine) |
| Metabolism | Hydrolysis by enzymes in red blood cells initially, subsequent metabolism follows |
| Metabolites | Dextroamphetamine (and its metabolites) and L-lysine |
| Onset of action | Oral: <2 hours |
| Elimination half-life | Lisdexamfetamine: <1 hour Dextroamphetamine: 10–12 h |
| Duration of action | 10–14 hours |
| Excretion | Kidney: ~2% |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C15H25N3O |
| Molar mass | 263.385 g·mol−1 |
| 3D model (JSmol) | |
| Chirality | Dextrorotatory enantiomer |
| |
| |
| | |
Főnév
lisdexamfetamine (tsz. lisdexamfetamines)
- lisdexamfetamine - Szótár.net (en-hu)
- lisdexamfetamine - Sztaki (en-hu)
- lisdexamfetamine - Merriam–Webster
- lisdexamfetamine - Cambridge
- lisdexamfetamine - WordNet
- lisdexamfetamine - Яндекс (en-ru)
- lisdexamfetamine - Google (en-hu)
- lisdexamfetamine - Wikidata
- lisdexamfetamine - Wikipédia (angol)